Literature DB >> 11074531

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.

S D Mikolajczyk1, L S Millar, K M Marker, T J Wang, H G Rittenhouse, L S Marks, K M Slawin.   

Abstract

BACKGROUND: We previously reported that levels of BPSA, a modified form of prostate-specific antigen (PSA), are significantly elevated in prostate transition-zone tissue exhibiting nodular hyperplastic changes associated with the presence of benign prostatic hyperplasia (BPH). BPSA was purified and found to contain a characteristic clip between Lys182 and Ser183. We now describe the identification of BPSA in seminal plasma.
METHODS: PSA was purified from seminal plasma by immunoaffinity chromatography. The purified PSA was further resolved by hydrophobic interaction chromatography, and the individual PSA forms were analyzed by gel electrophoresis and N-terminal amino-acid sequencing.
RESULTS: BPSA comprised about 8% of the PSA in pooled seminal plasma, and was identical to BPSA purified from prostate tissues. BPSA was cleanly resolved from all active and inactive forms of PSA. Other inactive forms of PSA in seminal plasma consisted largely of PSA clipped at Lys145, though about 30% of the inactive seminal plasma PSA was intact, mature PSA.
CONCLUSIONS: BPSA represents a distinct form of inactive PSA in the seminal plasma that may represent a specific marker for the biochemical changes associated with nodular development in the prostate transition zone found in patients with BPH. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074531     DOI: 10.1002/1097-0045(20001101)45:3<271::aid-pros11>3.0.co;2-t

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

2.  BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia.

Authors:  Kevin M Slawin; Shahrokh Shariat; Eduardo Canto
Journal:  Rev Urol       Date:  2005

Review 3.  [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].

Authors:  A Haese; M Graefen; J Palisaar; E Huland; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

Review 4.  [Isoforms of free prostate-specific antigen].

Authors:  A Haese; J Noldus; T Steuber; H Huland; H Lilja
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

Review 5.  Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.

Authors:  Jonathan M Levitt; Kevin M Slawin
Journal:  Curr Urol Rep       Date:  2007-07       Impact factor: 3.092

6.  Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.

Authors:  Akos Végvári; Melinda Rezeli; Charlotte Welinder; Johan Malm; Hans Lilja; György Marko-Varga; Thomas Laurell
Journal:  J Proteomics       Date:  2010-01-25       Impact factor: 4.044

7.  Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements.

Authors:  Erica L McJimpsey
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.